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Respiratory sensitization can be caused by a variety of substances at workplaces, and the health and economic burden linked to
allergicrespiratorydiseasescontinuestoincrease.Althoughthemainfactorsthataﬀecttheonsetofthesymptomsarethetypesand
intensity of allergen exposure, there is a wide range of interindividual variation in susceptibility to occupational/environmental
sensitizers. A number of gene variants have been reported to be associated with various occupational allergic respiratory diseases.
Examples of genes include, but are not limited to, genes involved in immune/inﬂammatory regulation, antioxidant defenses,
and ﬁbrotic processes. Most of these variants act in combination with other genes and environmental factors to modify disease
progression, severity, or resolution after exposure to allergens. Therefore, understanding the role of genetic variability and the
interaction between genetic and environmental/occupational factors provides new insights into disease etiology and may lead to
the development of novel preventive and therapeutic strategies. This paper will focus on the current state of knowledge regarding
genetic inﬂuences on allergic respiratory diseases, with speciﬁc emphasis on diisocyanate-induced asthma and chronic beryllium
disease.
1.Introduction
Workplace allergens can be categorized as either high or low
molecular weight allergens. Low molecular weight (LMW)
allergens such as diisocyanates, acid anhydrides, and metallic
salts are reactive chemicals with molecular weight less than
1000kD.They act as haptensand can cause sensitization that
may or may not be associated with speciﬁc immunoglobulin
E (IgE). While some LMW agents such as acid anhydrides,
platinum salts, and persulfates stimulate IgE antibodies,
many others including isocyanates and glutaraldehyde rarely
cause IgE-mediated sensitization [1]. On the other hand,
high molecular weight (HMW) protein-derived agents (e.g.,
proteases, ﬂour, and laboratory animal allergens) cause
allergic sensitization through mechanisms mediated by IgE
[2]. Early detection of sensitization is very important since
sensitized individuals can have life-threatening reactions to
future exposures even years after the cessation of exposure.
Although the risk of sensitization for individuals with un-
derlyingatopyishigherforsomeexposures(particularlyIgE-
mediated responses), high prevalence(around 20%) of atopy
in the general population indicates that atopy alone is not
the determining factor [3]. Although the main factors that
aﬀect the onset of the symptoms are the types, duration,
and intensity of allergen exposure, host genetic factors can
modulate how individuals interact with these agents and
induce a shift in the dose-response relationship [4]. Recent
genetic epidemiology research focused on common gene
variants and identiﬁed a number of genetic associations
and gene-environment interactions for allergic respiratory
diseases. Understanding gene-environment interactions is
especially important to improve occupational and public
health since environmental/occupational factors that inﬂu-
ence genetic risk are modiﬁable. In this respect, the results
of molecular epidemiology studies have the potential to be
used in risk evaluation and to help determine more accurate
safe occupational exposure levels, thereby contributing to
improved protection of workers at high risk. This paper will2 Journal of Allergy
summarize the contribution of genetic variability to two
important occupational respiratory diseases, diisocyanate-
induced asthma (DA) and chronic beryllium disease (CBD).
2.OccupationalAsthmaCaused
by Diisocyanates
Among LMW substances, the diisocyanates are the most
frequently reported cause of respiratory sensitization in the
workplace. These agents are widely used in polymerization
reactions for manufacturing surface coatings, varnishes,
paints, urethane foams, insulation, and adhesives. Workers
in these industries and workers that use these end products
may be inﬂuenced by potential adverse health eﬀects of
such chemicals. National Occupational Exposure Survey da-
tabase,National InstituteforOccupationalSafety andHealth
(NIOSH), showed that at least 280,000 workers were po-
tentially exposed to some form of isocyanates in the United
States alone [5]. Isocyanates are the leading cause of occu-
pational asthma (OA), estimated to cause asthma in 5–
10%ofchronicallyexposed workers[6–8].Despiteimproved
industrial hygiene eﬀorts, new cases of OA continue to occur
[9, 10]. The most common isomers used in industry are: the
aliphatic agent 1,6-hexamethylene diisocyanate (HDI), used
principally as a hardener in spray paints, 4,4-di-phenylmeth-
ane diisocyanate (MDI), and toluene diisocyanate (TDI).
Early diagnosis of OA leads to favorable clinical outcomes
(i.e., less risk of chronic and severe asthma) if aﬀected
workersare promptlyrecognized and removed fromharmful
exposure [9, 11]. In addition to early case detection, it is
also important to more closely monitor the most susceptible
workers at a preclinical stage.
Genetic epidemiologic studies have identiﬁed a number
of susceptibility markers for a variety of asthma phenotypes
including OA. Most of these genetic studies were hindered
by diﬃculty in deﬁning asthma, a complex phenotype repre-
senting allergic and nonallergic types. This has led to selec-
tion of intermediate or quantiﬁable phenotypes (e.g., airway
hyperresponsiveness, lung function, and serum IgE levels) in
some association studies. On the other hand, OA is a unique
model in that the phenotype can be deﬁned accurately by
speciﬁc inhalation challenge (SIC) testing often considered
the gold standard for diagnosing OA [12] .F o rt h i sr e a s o n ,
OA is an excellent model for studying gene-environment
interactions since the causal agent can be identiﬁed with SIC
and the lag period between initial exposure and onset of
sensitization and clinical symptoms can be followed [13].
Given its immune-inﬂammatory nature, OA phenotypes
are likely associated with speciﬁc variants of immune-/in-
ﬂammatory-related genes. Linkage studies have suggested a
variety ofcandidategenesforasthma and related phenotypes
in chromosomal regions 2q14-q32, 5q31-q33, 6p24-p21,
7p15-p14, 11q13-q21, 12q21-q24, 13q12-q14, and 20p13
[14–21]. In particular, variants ofinterleukin (IL)-4,IL-4RA,
IL-13, β-adrenergic receptor (β-AR), tumor necrosis factor
(TNF)-α, human leukocyte antigen (HLA)-DRB1, DQB1,
the β-subunit of the high-aﬃnity IgE receptor (FceRI),
CD14, a disintegrin and a metalloproteinase 33 (ADAM33)
genes have been consistently associated with asthma-related
phenotypes in independent studies [22, 23]. As in other
forms ofasthma, inﬂammatory changes andallergen-speciﬁc
T-lymphocytes are found in the airways of many patients
with OA, along with eosinophils, cytokines, and serum IgE
antibodies [24–26]. Thus, similar genetic associations as in
immune-mediated asthma might be expected to occur in
OA. Although a number of genetic association studies have
been conducted on individuals with allergic asthma from
environmental causes, there are only limited studies on OA.
The Human Leukocyte Antigen (HLA) class II molecules
play a role in the presentation of intracellularly processed
peptides to CD4+ T-helper cells. HLA class II molecules
are highly polymorphic and the variations in their protein
structure may determine the speciﬁc epitopes presented to
T cells. Therefore, HLA class II molecules are also plausible
candidates for controlling speciﬁc immunological responses
toallergens. Genetic studiesinvestigating the immunopatho-
genesis of OA have focused on HLA Class II alleles. Bignon
et al. demonstrated that HLA DQB1∗0503 and the allelic
combination DQB1∗0201/0301 were associated with sus-
ceptibility to DA [27]w h e r e a st h eD Q B 1 ∗0501 allele and
the DQA1∗0101-DQB1∗0501-DR1 haplotype were con-
sidered protective. Subsequently, Mapp et al. conﬁrmed the
association with HLA-DQB1∗0503 and reported that the
DQA1∗0104 allele was increased in DA compared with
asymptomatic exposed workers. They also showed that
“protective” alleles, HLA-DQB1∗0501 and DQA1∗0101,
were increased in asymptomatic exposed workers versus
those with DA [19]. In another study, a signiﬁcantly higher
proportion of subjects with DA were found to express
the HLA-DQB1∗0503-associated aspartic acid at residue 57
[28]. HLA associations with DA were also investigated in a
population of Asian workers exposed to diisocyanates but
theassociations foundin Europeanworkers were notentirely
replicated. The HLA haplotypes DRB1∗15-DPB1∗05 and
HLA DRB1∗1501-DQB1∗0602-DPB1∗0501 were reported
as a susceptibility marker for the development of TDI-
induced asthma in Koreans [29, 30]. Bernstein et al., in-
vestigated association between known SNPs in immune
response genes (IL-4Rα, IL-13, and CD14) and DA in a
group of exposed workers undergoing SIC testing. The re-
sults demonstrated increased frequencies of IL-4RA I50V
allele and combinatorial genotypes of IL4RA (I50V), IL-
13 (R110Q), and CD14 (C159T) in HDI-exposed workers
suggesting an exposure-speciﬁc interaction [31]. These ﬁnd-
ing supported the notion that immune mechanisms play an
important role in the pathogenesis of DA.
Since isocyanates are known to cause oxidative injury
to respiratory epithelial cells, variations within antioxidant
defense genes have been examined in workers with DA [32].
Glutathione, a major antioxidant protein found in the bron-
chial lining ﬂuid and in respiratory epithelial cells, is likely to
serve a protective function by binding with free isocyanate
molecules and, thereby, preventing damage to respiratory
epithelial cells or intracellular binding to respiratory epithe-
lial proteins or proteins in the bronchial lumen [33]. Piiril¨ a
etal.examinedpolymorphismsoftheglutathioneS-transfer-
ase (GST) genes (GSTM1, GSTM3, GSTP1, and GSTT1) inJournal of Allergy 3
workers with DA. GSTM1 null genotype was associated
with a 1.89-fold risk of DA. Subjects with GSTM1 null and
GSTM3 AA genotypes developed late reaction in the speciﬁc
bronchialprovocationtestwithdiisocyanates, individuallyor
in combination [34]. Later, Mapp et al. assessed the GSTP1
gene in TDI-exposed asymptomatic and asthmatic workers
[18].The frequencyoftheGSTP1Ile105ValVal/Valgenotype
was lower in subjects with DA, and was signiﬁcantly lower
among subjects with airway hyperresponsiveness. In another
study, the N-acetyltransferase (NAT1) slow acetylator gen-
otype was associated with a 2.5-fold risk of OA among di-
isocyanate-exposed workers. Interestingly, a far greater 7.77-
fold risk of OA was reported among workers exposed
to TDI, suggesting an exposure-speciﬁc association. In
addition, a gene-gene interactive eﬀect was identiﬁed in di-
isocyanate-exposed workers with the combined NAT1 or
NAT2 slow acetylator genotypes and GSTM1 null genotype
[35]. Broberg et al. investigated the inﬂuence of variants in
TDI-metabolizing genes on the associations between TDI
in air (2,4-TDI and 2,6-TDI) and its metabolites toluene
di-amine (2,4-TDA and 2,6-TDA) in plasma and urine.
Their results showed that the GSTP1 Ile105Val variant
modiﬁes the association between 2,4-TDA in plasma and
in urine, supporting the importance of GST system for the
metabolism of TDI [36]. Based on the role of neurogenic
inﬂammation in TDI-induced airway hyperresponsiveness,
the association between neurokinin-2 receptor (NK2R) gene
polymorphismsandTDI-inducedasthma wasinvestigatedin
a Korean population. An association was found between the
NK2R 7853GG genotype and increased serum VEGF levels,
suggesting that NK2R variants may modulate the airway
inﬂammation conferred by VEGF [37]. Another Korean
study investigated the possible role of β2-adrenergic receptor
gene (ADRB2) polymorphisms in TDI-induced asthma. The
Arg16Gly A>G, Leu134Leu G>A, and Arg175Arg C>A SNPs
and haplotype [TTACGC] were found to be associated with
speciﬁc IgE sensitization in TDI-exposed workers [38]. In
another study, genome-wide association was performed to
identify susceptibility alleles associated with asthma induced
by TDI. The results showed signiﬁcant association between
genetic polymorphisms (rs10762058, rs7088181, rs4378283,
and rs1786929) of catenin α3 (CTNNA3) and susceptibility
to TDI-induced asthma [39]. The CTNNA3 variants have
been suggested to inﬂuence TDI-induced asthma risk by
increasing epithelial damage and airway inﬂammation.
3.ChronicBerylliumDisease
Chronicberyllium disease (CBD)isa seriousgranulomatous
lung disease caused by beryllium (Be) exposure in the work-
place.CBDcontinuestooccurinindustries whereBeisman-
ufactured and processed such as aerospace, nuclear, automo-
tive, and electronics. NIOSH estimated that up to 134,000
workers in the United States were exposed to beryllium
[40]. Be exposure leads to a cell-mediated hypersensitivity
(delayed, type IV) reaction in which Be haptenates native
proteins leading to the production of the speciﬁc allergen
[41]. It is known that accumulation of Be-speciﬁc CD4(+)
T cells and persistent lung inﬂammation play a key role in
the immunopathogenesis of CBD. Prior to the development
of CBD, many exposed workers become sensitized and many
of those eventually develop CBD. Approximately 50% of
sensitized individuals have CBD at initial clinical evaluation
[42]. Be-speciﬁc T-cell proliferative responses are detected
in the blood of exposed workers using the Be lymphocyte
proliferation test (BeLPT) [43, 44]. The BeLPT has been
shown to identify approximately 70 to 94% of cases of BeS
and CBD and widely used in screening and surveillance
of Be-exposed workers [45–47]. Epidemiological studies
showed the prevalence rates of BeS and CBD to be between
5–21% and 3–21% among beryllium workers, respectively
[48, 49]. The pathologic progression from BeS to CBD is
not well understood warranting further research into the
pathophysiological mechanisms and susceptibility markers
of BeS and CBD. Such eﬀorts will be important for early
detection and disease prevention in Be-exposed workers.
A number of molecular epidemiology studies showed
that the presence of glutamic acid in position 69 of the B1
chain of the HLA-DPB1 molecule confers an increased risk
for both BeS and CBD [41, 50–54]. The HLA-DPB1Glu69
frequency was reported to be between 39–90% in sensitized
workers and 53–97% in workers with CBD as compared
to 19–48% in nonsensitized workers [41, 50–52, 55–61].
Importantly, studies have demonstrated a dose-dependent
eﬀect of HLA-DPB1Glu69 alleles suggesting that Glu69
is a potential marker of disease severity in addition to
overall disease risk [41]. Although HLA-DPB1Glu69 is more
frequent in individuals with BeS and CBD (73–95%), 30–
40% of exposed workers carrying HLA-DPB1Glu69 do not
develop CBD or BeS [41, 50, 62]. This suggests that other
host and environmental factors likely play key roles in the
pathogenesis of CBD. Studies investigating the interaction
b e t w e e nt h eH L A - D P B 1G l u 6 9a n dB ee x p o s u r es h o w e d
independent and additive eﬀects of Glu69 carriage and Be
exposure in the development of BeS and CBD [58, 63].
Rossmanetal.reported thatHLA-DQB1Gly86andHLA-
DRB1Ser11 alleles occurred more often in individuals with
CBD [55] .M a i e re ta l .f o u n dt h a tH L A - D R B 1 ∗01 and
DQB1∗05 alleles were less frequent in workers with CBD.
They also reported that DRB1∗13 and DQB1∗06 were
associated with CBD in the absence of Glu69 [41]. A recent
study showed that the DRβE71 allele is a risk factor for
both CBD and BeS in the absence of Glu69 and highlighted
the importance of interactions between peptides and T cells
in the development of CBD [61]. Chemically speciﬁc Be-
protein interactions were also investigated using a com-
putational approach. Glu69 alleloforms with the greatest
negative surface charge were found to confer the highest risk
for CBD and irrespective of allele, equal risk for BeS [64].
CurrentHLAresearch includesinvestigating whethertherisk
is associated with any or only certain Glu69 alleles or allelic
combinations.
Non-HLAgenetic studiesalso identiﬁed some signiﬁcant
associations. Sato et al. investigated eight SNPs within CCR5
gene that is implicated in the chemotaxis and activation of
leukocyte subsets. The results showed that CCR5-5663 and
-3458 variants were associated with worsening pulmonary4 Journal of Allergy
Table 1: Examples of genetic associationsfor DA and CBD.
Disease Gene Variation RR; P value; OR (95% CI) Reference
DA
HLA-DQB1 ∗0503 RR = 9.8,P<. 04 [27]
HLA-DQB1 ∗0501 RR = 0.14,P<. 03 [27]
HLA-DQA1 ∗0104 P = .008 [19]
HLA-DRB1-DPB1 ∗15∗05 P = .001 [29]
GSTM1 Null 1.89 (1.01–3.52) [34]
NAT1 Slow acetylator 7.77 (1.18–51.6) [35]
IL4RA, IL-13 R, CD14 I50V-R110Q-C159T 6.4 (1.57–26.12) [31]
CTNNA3 rs1786929 P = .015 [39]
CBD
HLA-DPB1 Glu69 9.4 (5.4–16.6) [50]
HLA-DQB1 G86 P<. 04 [55]
HLA-DRB1 S11 P<. 03 [55]
CCR5 -3458 P<. 0001 [65]
TGFβ1 -509 P = .01 [66]
GCLC TNR 7/7 0.28 (0.08–0.95) [67]
GCLM -588 C/C 3.07 (1.00–9.37) [67]
IL-1A -1142 3.02 (1.36–6.70) [69]
-3769 2.51 (1.21–5.19) [69]
-4697 2.56 (1.24–5.29) [69]
RR:relative risk; OR:odds ratio.
function over time in CBD [65]. The -509C and codon 10T
variants of the transforming growth factor-β1( T G F β) gene,
a cytokine with a major role in the ﬁbrotic/Th1 response,
were found to be associated with more severe granulomatous
disease in CBD [66]. Since glutathione has been reported
to be increased in CBD, genetic variants of the glutamate
cysteine ligase (GCL), a rate-limiting enzyme in GSH syn-
thesis, were investigated. GCL consists of a catalytic subunit
(GCLC) and modiﬁer subunit (GCLM). GCLC trinucleotide
repeat polymorphism (7/7 genotype) and the GCLM-588
SNP were found to be associated with altered susceptibility
to CBD [67]. While Saltini et al. reported an association
between the TNFα-308∗02 variant and BeS and CBD, this
result was not conﬁrmed in a large population-based study
[57, 68]. A recent study showed that IL-1α-1142, -3769,
and -4697 variants were signiﬁcantly associated with CBD
compared to individuals with BeS or nonsensitized workers
after adjusting for Glu69 status [69]. These results suggested
that the formation of granulomas in CBD may require
an independent inﬂammatory response controlled by genes
unrelated to beryllium recognition. Table 1 lists some exam-
ples of associations found for both DA and CBD.
4.Conclusions
Genetic association studies can provide more accurate in-
formation on the interindividual variability, thereby con-
tributing to establishment of more accurate exposure limits
in the workplace. These eﬀorts, in a larger perspective, pro-
vide opportunities to eﬀectively target engineering controls,
personalprotectiveequipment,andinterventionstrategiesto
protect the health of high-risk workers. With the advances in
high-throughput technologies and computational method-
ologies, this information could be used in designing better
predictive models to incorporate genetic variability into risk
evaluation and improving the regulation and redeﬁnition of
acceptable exposure levels in the workplace. Success of such
approaches dependson how molecular epidemiologystudies
overcome some of the current challenges. Despite the rapid
growth of published associations, some of the genetic associ-
ations lack consistency across diﬀerent studies. The inconsis-
tencyinresultsmightbeexplainedbythediﬀerencesinstudy
populations, phenotype characterization, exposure assess-
ment, characterization of other environmental exposure
(e.g., air pollution, smoking), intermediate phenotypes (e.g.,
airway hyperresponsiveness), statistical inconsistencies and
other potentially modiﬁable risk factors such as lifestyle. For
example, allele/carrier frequencies of the HLA-DPB1Glu69
ranged between 0.21/0.38 to 0.33/0.59 across diﬀerent
ethnic populations [70]. This emphasizes the importance
of replication studies in independent populations with
ad i ﬀerent genetic background. Although the genetics of
allergic respiratory diseases including DA and CBD have
yet to be fully characterized, summarized discoveries hold
promise for the identiﬁcation of susceptibility proﬁles and
characterization of gene-environment interactions. It is to
be hoped that future genetic association studies with large,
well-characterized populations through national and inter-
nationalcollaborationswillincreasetheunderstandingofthe
pathogenesis of these diseases and help identify novel thera-
peutictargetsandpreventative/educationalstrategiesforbet-
ter identiﬁcation and management of occupational diseases.Journal of Allergy 5
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